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Introduction: 
Warfarin has been a mainstay of therapy for treatment and prevention of venous 
thromboembolic disease (VTED) and prevention of stroke and systemic embolism 
for over 50 years. Recent FDA approval of several novel oral anticoagulants has 
offered more extensive treatment options for management of these disease states. 
The availability of the novel anticoagulants offers an attractive alternative to warfarin 
therapy for  patients due to their convenience of use. In comparison to warfarin, 
dabigatran, rivaroxaban and apixaban offer: 
 - a fixed dosage regimen
 - a relatively small potential drug interaction profile
 - minimal laboratory monitoring
 - little to no dietary restrictions. 
Although these agents offer a relatively fixed dose regimen, dosage adjustment is 
required in moderate renal dysfunction, and use is contraindicated in severe renal 
dysfunction. Currently there are no specific reversal agents in the event of a nov-
el anticoagulant associated bleed. These concerns led to the development of an 
anticoagulation stewardship program at our institution to monitor and guide the 
usage of these agents.
Background of the Program:
Thomas Jefferson University Hospital is a 957 licensed acute care bed 
academic medical center with 3 hospital locations in the Philadelphia 
area, including a facility in center city, South Philadelphia and a neuro-
science hospital. Our neuroscience hospital, JHN, is the only hospital 
dedicated to the treatment of neurological diseases in the Philadelphia 
region, and receives a large number of transfers from hospitals within the 
tri-state area for management of intracranial hemorrhages, including 
those associated with anticoagulation use.
In an effort to insure the safe and appropriate use of the novel 
anticoagulants and timely management of admissions from the 
community for associated adverse events, a steering committee of 
specialized physicians and pharmacists met to develop a comprehensive 
management program, which includes:
 - guidelines for use
 - an educational program
 - CPOE order sets
 - a surveillance program
 -monitoring criteria with recommended laboratory assays
 - perioperative management guidelines
 - emergency management response process
A care transitions program was also developed to insure proper 
communication of care plans and follow-up after discharge, and to, 
hopefully, prevent adverse events and readmissions.
 
 
Below are some examples of the program components
 
Our Experience
Impact of Community Prescribing on Our Institution:
The use of dabigatran, rivaroxaban and apixaban has resulted in increased 
workload on our pharmacy team to insure safe and appropriate 
utilization of these agents. The majority of interventions has occurred at 
time of admission, and mainly has involved either: suboptimal patient 
selection, dosing or inappropriate management in the perioperative 
period. A summary of the interventions are listed below.
Adverse Events
As part of an ongoing quality and safety initiative, bleeding events 
associated with novel anticoagulant use are being monitored in 
hospitalized patients at our institution. All hemorrhagic events occurred 
within the community and resulted in an admission to our hospital 
system, mainly at our neuroscience hospital. A summary of these adverse 
events and cost of care is listed below:
Summary of Adverse Events and Patient Characteristics
8 patients were admitted to TJUH  from November 2011 to May 2012 
for bleeding, all were associated with dabigatran use.  Six patients were 
transferred from an outside hospital to our neuroscience hospital for 
ICH management.  All patients were on anticoagulation for atrial 
fibrillation, the most commonly prescribed dose of dabigatran was 150mg 
BID.  Average pt age was 80.3 yrs. (range 63-90).  
Average admission serum creatinine was 1.8 mg/dL (range 0.5-3.0). 
Female to Male 1:1. Strategies for the management of bleeding included 
withholding dabigatran, supportive care, administration of blood 
products and hemodialysis, when required.  Dialysis was initiated on 3 
patients, conventional +/ - CVVHD.
One patient died.
The average aPTT on admission was 69 seconds (range 32-170).
The average ICU length of stay was 10.4 days (range 0-39), with an 
average ICU cost of $28,883.75. Total inpatient cost averaged 
$46,603.00m with a cost range of $15,963.00 – 160,899.00. The 
average length of stay was 14 days (range 5-44).
Conclusions:
The perceived ease of use of the novel anticoagulants has resulted in an 
increasingly popular utilization of these agents in the outpatient 
population as an alternative to warfarin therapy. These agents are 
frequently employed in the elderly population, since it is often difficult 
for this group of patients to go to their doctor’s office or a laboratory for 
the required laboratory testing needed with warfarin management, 
mainly due to transportation and health issues. 
These anticoagulants must be used with caution in certain subsets of 
patients, including the frail elderly or those with comorbidities which 
increase the risk for unstable and declining renal function. We have found 
that development and implementation of screening and educational tools 
were very useful in insuring appropriate patient selection by providing 
ongoing education to the house staff; we have experienced relatively little 
problems with new inpatient orders for these agents. Most of our efforts 
have involved adjustment and alteration of orders at the time of 
admission for patients chronically prescribed novel anticoagulants as 
outpatient therapy. 
Experience from our stewardship program has shown that many orders 
from the community require alteration to another more optimal 
anticoagulant agent or adjustment of dose due to factors that increase the 
risk for drug accumulation and development of adverse events. 
Novel anticoagulant adverse events can be difficult to manage and result 
in long ICU stays and high healthcare costs. Widespread use within the 
community has lead to increased workload on our pharmacy and 
medical staff to assess and adjust inappropriate usage. A formalized 
transition of care program is necessary to: insure appropriate monitoring 
and follow up after discharge, insure adequate communication of care 
plans to outpatient physicians, enhance patient understanding and com-
pliance with treatment / follow-up, and insure optimal patient outcomes.
The Impact of Community Use of Novel Oral Anticoagulants on an Academic Medical Center
Luis Eraso, M.D, Taki Galanis, M.D., Kristina Kipp, Pharm.D., Walter K. Kraft, M.D., Michael Palladino, Pharm.D., Alejandro Perez, MD., Kimberle Ferebee – Spruill, CRNP, 
Geno Merli, M,D., Brian Swift, Pharm.D., Lynda Thomson, Pharm.D, Brittany Vining.
Thomas Jefferson University Hospital, Philadelphia, PA, United States
Presenters: Alyssa Gumkowski, Geno Merli, M.D., Kimberle Ferebee-Spruill, CRNP
Dabigatran Inclusion and Exclusion Criteria
Approved by P&T Committee and Medical Executive Committee Spring 
2011
New inpatient requests for dabigatran should be screened for appropriateness 
of use. Use of dabigatran not meeting inclusion criteria would require a 
consult from Cardiology, Vascular Medicine (JATS), or Cardeza to approve 
use in the inpatient setting.
A. Inclusion criteria:
Prevention of stroke and systemic embolism in patients with non-valvular 
atrial fibrillation
B. Exclusion criteria:
Patients with atrial fibrillation and history of mitral valve stenosis, 
valvuloplasty or rheumatic heart disease. 
Infectious endocarditis
Patients with a previous stroke within the past 6 months
Conditions associated with an increased risk of bleeding, including, but not 
limited to:
•	 Major	surgery	within	the	past	month
•	 History	 of	 intracranial,	 intraocular,	 spinal,	 retroperitoneal,	 
 gastrointestinal or atraumatic intra-articular  bleeding
•	 History	of	a	hemorrhagic	disorder,	including	hemophilia
•	 Active	malignancies	of	a	highly	vascular	nature
Symptomatic or endoscopically documented gastroduodenal ulcer, Crohn’s 
disease, ulcerative colitis or severe GERD
Pt unable to swallow an intact pill, such as patients with an enteral feeding 
tube
Uncontrolled hypertension (systolic blood pressure >180 mm Hg and/or dia-
stolic blood pressure > 100 mm Hg)
Severe renal dysfunction (i.e. CrCl < 30 ml/min) or unstable renal function 
with declining urine output (<0.5 ml/kg/hr based on ideal body weight) in a 
patient with a baseline CrCl < 50 ml/min
Age < 18 years of age
Pregnant or nursing mothers
Active liver disease, including ALT, AST, Alk Phos > two times upper normal 
limits, active Hepatitis A,B,C
Clinically significant anemia (Hgb < 10g/dl)
Thrombocytopenia (platelet count < 100 X 103/L)
Known history of non-compliance
No prescription coverage or means to acquire medication
Concomitant use of Rifampin
C. Relative Contraindications
 o Advanced age > 75 years of age 
 o Caution should be exercised in certain high risk populations,  
  such as combined  advanced age (>75 years), with low body  
  weight and / or renal dysfunction (CrCl < 50 ml/min)
 o Concomitant antiplatelet therapy: prasugrel, clopidogrel, 
  aspirin or NSAIDS
 o Pt requiring ongoing repeat interruption of therapy for 
  invasive procedures, e.g. patient with ascites requiring repeat  
  paracentesis procedures
 o Concomitant therapy with other drugs known to be major 
  p-glycoprotein inducers or inhibitors, e.g. amiodarone, 
  quinidine
 o Prior history of MI or unstable angina
Novel Anticoagulation Stewardship Program Percentage of Novel Anticoagulant Orders  
Requiring Intervention
Rivaroxaban Intervention by Type (%) N=67
Dabigatran Orders Requiring Intervention by Type (%) 
N=71
Hospital Novel Anticoagulant Emergency  
Management Team
Dabigatran Surveillance Program (2 year period)
93% of all orders required an intervention
Average patient age: 73 yrs.  Age Range 35 – 90 yrs.
Average patient weight: 83 kg  Weight Range: 40 – 179 kg
Majority of interventions required in the “frail elderly” population 
Frequent interventions included: switching to a more appropriate anticoagulant due to poor 
renal function, dosage adjustment and discontinuation of duplicate anticoagulants: e.g. 
subcutaneous heparin ordered for “DVT prophylaxis” with dabigatran.
Rivaroxaban Surveillance Program (1 year period)
68 % of all orders required an intervention 
Average patient age:  61 yrs.  Age Range 15 – 91 yrs.
Average patient weight:  82 kg   Weight Range:  36 – 157 kg
Majority of interventions required in the “frail elderly” population, requiring conversion to 
a more appropriate anticoagulant due to unstable and / or declining renal function, often in 
the setting of advanced CHF. Alteration in concomitant medication regimens required for 
contraindicated medications, including carbamazepine use in a patient being treated with 
rivaroxaban for a Saddle Pulmonary Embolism.
Apixaban Surveillance Program: Implementation pending official approval for 
formulary addition
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Average Total  Cost of Care
$46,603.00
Total Cost of Care Range
$15,963.00 – 160,899.00
Total Cost of Care
As expected, the inpatient cost for caring for patients admitted with a 
novel anticoagulant associated bleeding event was high, with the highest 
costs incurred in patients admitted with an intracranial hemorrhage and 
those requiring hemodialysis for emergency management.
Novel Anticoagulant
Dabigatran
Rivaroxaban
Apixaban
FDA Approval Date
October 19, 2010
November 4, 2011
November 2, 2012
December 28, 2012 
Approved Indication
Prevention of stroke and 
systemic embolism
Prevention of stroke and 
systemic embolism
Treatment acute and chronic VTED
Prevention of stroke and 
systemic embolism
